Schizandrin B inhibits the cis‑DDP‑induced apoptosis of HK‑2 cells by activating ERK/NF‑κB signaling to regulate the expression of survivin

Liu,Qiang; Song,Jinxin; Li,Hong; Dong,Lei; Dai,Shejiao

doi:10.3892/ijmm.2018.3409

Schizandrin B inhibits the cis‑DDP‑induced apoptosis of HK‑2 cells by activating ERK/NF‑κB signaling to regulate the expression of survivin

Authors:
- Qiang Liu
- Jinxin Song
- Hong Li
- Lei Dong
- Shejiao Dai
View Affiliations

Affiliations: Department of Medical Imaging, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Department of Ophthalmology, The First Hospital of Xi'an, Xi'an, Shaanxi 710002, P.R. China, Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China
Published online on: January 19, 2018 https://doi.org/10.3892/ijmm.2018.3409
Pages: 2108-2116
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The nephrotoxicity of cisplatin limits its clinical application. Schizandrin B (SchB) has been demonstrated to have a variety of potential cytoprotective activities. The present study explored the molecular mechanisms by which SchB inhibits the dichlorodiammine platinum (DDP)‑induced apoptosis of HK‑2 proximal tubule epithelial cells. In vitro assays demonstrated that SchB increased the viability of HK‑2 cells, alleviated the cis‑DDP‑induced activation of caspase‑3, reduced apoptosis and improved the nuclear morphology of HK‑2 cells. Additionally, the mechanism underlying the cis‑DDP‑induced apoptosis was indicated to involve the activation of p53, c‑Jun‑N‑terminal kinase (JNK) and p38 signaling. Furthermore, SchB was demonstrated to activate extracellular signal‑regulated kinase (ERK) and nuclear factor κB (NF‑κB) signaling, and induce the expression of survivin. The inhibition of ERK and NF‑κB signaling using U0126 and pyrollidine dithiocarbamate, respectively, inhibited the expression of survivin, whereas blocking the expression of survivin using small interfering RNA inhibited the alleviating effect of SchB on cis‑DDP‑induced apoptosis as indicated by a reduction in cleaved caspase‑3 expression. In conclusion, SchB regulates ERK/NF‑κB signaling to induce the expression of survivin, thereby alleviating cis‑DDP‑induced renal injury.

View Figures

View References

1	Einhorn LH: Curing metastatic testicular cancer. Proc Natl Acad Sci USA. 99:4592–4595. 2002. View Article : Google Scholar : PubMed/NCBI
2	Karasawa T and Steyger PS: An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 237:219–227. 2015. View Article : Google Scholar : PubMed/NCBI
3	Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, Rassekh SR, Chang KW, Fligor BJ, Rajput K, et al: Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 30:2408–2417. 2012. View Article : Google Scholar : PubMed/NCBI
4	McWhinney SR, Goldberg RM and McLeod HL: Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 8:10–16. 2009. View Article : Google Scholar : PubMed/NCBI
5	Shen DW, Pouliot LM, Hall MD and Gottesman MM: Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
6	Yao X, Panichpisal K, Kurtzman N and Nugent K: Cisplatin nephrotoxicity: A review. Am J Med Sci. 334:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
7	Nozaki Y, Kinoshita K, Hino S, Yano T, Niki K, Hirooka Y, Kishimoto K, Funauchi M and Matsumura I: Signaling Rho-kinase mediates inflammation and apoptosis in T cells and renal tubules in cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 308:F899–F909. 2015. View Article : Google Scholar : PubMed/NCBI
8	Hagar H, Medany AE, Salam R, Medany GE and Nayal OA: Betaine supplementation mitigates cisplatin-induced nephrotoxicity by abrogation of oxidative/nitrosative stress and suppression of inflammation and apoptosis in rats. Exp Toxicol Pathol. 67:133–141. 2015. View Article : Google Scholar
9	Chen Q, Peng H, Dong L, Chen L, Ma X, Peng Y, Dai S and Liu Q: Activation of the NRF2-ARE signalling pathway by the Lentinula edodes polysaccharose LNT alleviates ROS-mediated cisplatin nephrotoxicity. Int Immunopharmacol. 36:1–8. 2016. View Article : Google Scholar : PubMed/NCBI
10	Ma X, Dang C, Kang H, Dai Z, Lin S, Guan H, Liu X, Wang X and Hui W: Saikosaponin-D reduces cisplatin-induced nephrotoxicity by repressing ROS-mediated activation of MAPK and NF-κB signalling pathways. Int Immunopharmacol. 28:399–408. 2015. View Article : Google Scholar : PubMed/NCBI
11	Francescato HD, Costa RS, Silva CG and Coimbra TM: Treatment with a p38 MAPK inhibitor attenuates cisplatin nephrotoxicity starting after the beginning of renal damage. Life Sci. 84:590–597. 2009. View Article : Google Scholar : PubMed/NCBI
12	Mishima K, Baba A, Matsuo M, Itoh Y and Oishi R: Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free Radic Biol Med. 40:1564–1577. 2006. View Article : Google Scholar : PubMed/NCBI
13	Ramesh G and Reeves WB: p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol. 289:F166–F174. 2005. View Article : Google Scholar : PubMed/NCBI
14	Shao Y, Le K, Cheng H and Aplin AE: NF-κB regulation of c-FLIP promotes TNFα-mediated RAF inhibitor resistance in melanoma. J Invest Dermatol. 135:1839–1848. 2015. View Article : Google Scholar : PubMed/NCBI
15	Tsubaki M, Ogawa N, Takeda T, Sakamoto K, Shimaoka H, Fujita A, Itoh T, Imano M, Satou T and Nishida S: Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-κB nuclear translocation and down-regulation of Bcl-xL and XIAP. Biomed Pharmacother. 68:999–1005. 2014. View Article : Google Scholar : PubMed/NCBI
16	Yang T, Lan J, Huang Q, Chen X, Sun X, Liu X, Yang P, Jin T, Wang S and Mou X: Embelin sensitizes acute myeloid leukemia cells to TRAIL through XIAP inhibition and NF-κB inactivation. Cell Biochem Biophys. 71:291–297. 2015. View Article : Google Scholar
17	Hughes MA, Powley IR, Jukes-Jones R, Horn S, Feoktistova M, Fairall L, Schwabe JW, Leverkus M, Cain K and MacFarlane M: Co-operative and hierarchical binding of c-flip and caspase-8: A unified model defines how c-flip isoforms differentially control cell fate. Mol Cell. 61:834–849. 2016. View Article : Google Scholar : PubMed/NCBI
18	Elsawy MA, Martin L, Tikhonova IG and Walker B: Solid phase synthesis of Smac/DIABLO-derived peptides using a ‘Safety-Catch’ resin: Identification of potent XIAP BIR3 antagonists. Bioorg Med Chem. 21:5004–5011. 2013. View Article : Google Scholar : PubMed/NCBI
19	Kwan HY, Niu X, Dai W, Tong T, Chao X, Su T, Chan CL, Lee KC, Fu X, Yi H, et al: Lipidomic-based investigation into the regulatory effect of schisandrin B on palmitic acid level in non-alcoholic steatotic livers. Sci Rep. 5:91142015. View Article : Google Scholar : PubMed/NCBI
20	Pao TT, Hsu KF, Liu KT, Chang LG, Chuang CH and Sung CY: Protective action of schizandrin B on hepatic injury in mice. Chin Med J. 3:173–179. 1977.PubMed/NCBI
21	Yang T, Liu S, Zheng TH, Tao YY and Liu CH: Comparative pharmacokinetics and tissue distribution profiles of lignan components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe. J Ethnopharmacol. 166:305–312. 2015. View Article : Google Scholar : PubMed/NCBI
22	Jiang EP, Li H, Yu CR, Yu CY, Jing S, Sun HX, Wang CM, Fan XT, Chen JG and Wang S: Schisandrin B protects PC12 cells against oxidative stress of neurodegenerative diseases. Neuroreport. 26:360–366. 2015. View Article : Google Scholar : PubMed/NCBI
23	Stacchiotti A, Li Volti G, Lavazza A, Schena I, Aleo MF, Rodella LF and Rezzani R: Different role of schisandrin B on mercury-induced renal damage in vivo and in vitro. Toxicology. 286:48–57. 2011. View Article : Google Scholar : PubMed/NCBI
24	Thandavarayan RA, Giridharan VV, Arumugam S, Suzuki K, Ko KM, Krishnamurthy P, Watanabe K and Konishi T: Schisandrin B prevents doxorubicin induced cardiac dysfunction by modulation of DNA damage, oxidative stress and inflammation through inhibition of MAPK/p53 signaling. PLoS One. 10:e01192142015. View Article : Google Scholar : PubMed/NCBI
25	Chiu PY, Leung HY, Poon MK, Mak DH and Ko KM: (−) Schisandrin B is more potent than its enantiomer in enhancing cellular glutathione and heat shock protein production as well as protecting against oxidant injury in H9c2 cardiomyocytes. Mol Cell Biochem. 289:185–191. 2006. View Article : Google Scholar : PubMed/NCBI
26	Lv XJ, Zhao LJ, Hao YQ, Su ZZ, Li JY, Du YW and Zhang J: Schisandrin B inhibits the proliferation of human lung adenocarcinoma A549 cells by inducing cycle arrest and apoptosis. Int J Clini Exp Med. 8:6926–6936. 2015.
27	Bunel V, Antoine MH, Nortier J, Duez P and Stévigny C: Protective effects of schizandrin and schizandrin B towards cisplatin nephrotoxicity in vitro. J Appl Toxicol. 34:1311–1319. 2014. View Article : Google Scholar
28	Fernandes-Alnemri T, Litwack G and Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem. 269:30761–30764. 1994.PubMed/NCBI
29	Reed JC and Reed SI: Survivin’ cell-separation anxiety:. Nat Cell Biol. 1:E199–E200. 1999. View Article : Google Scholar : PubMed/NCBI
30	Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC and Altieri DC: Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol. 1:461–466. 1999. View Article : Google Scholar : PubMed/NCBI
31	Dong Q, Hou H, Wu J and Chen Y: The Nrf2-ARE pathway is associated with Schisandrin B attenuating benzo(a) pyrene-Induced HTR cells damages in vitro. Environ Toxicol. 31:1439–1449. 2016. View Article : Google Scholar : PubMed/NCBI
32	Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH and Sparreboom A: Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 86:396–402. 2009. View Article : Google Scholar : PubMed/NCBI
33	Pabla N, Murphy RF, Liu K and Dong Z: The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 296:F505–F511. 2009. View Article : Google Scholar : PubMed/NCBI
34	Juo P, Kuo CJ, Yuan J and Blenis J: Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol. 8:1001–1008. 1998. View Article : Google Scholar : PubMed/NCBI
35	Liu H and Baliga R: Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis. J Am Soc Nephrol. 16:1985–1992. 2005. View Article : Google Scholar : PubMed/NCBI
36	Omar HA, Mohamed WR, Arab HH and Arafa el-SA: Tangeretin alleviates cisplatin-induced acute hepatic injury in rats: Targeting MAPKs and apoptosis. PLoS One. 11:e01516492016. View Article : Google Scholar : PubMed/NCBI
37	Matsumoto M, Nakajima W, Seike M, Gemma A and Tanaka N: Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. Biochem Biophys Res Commun. 473:490–496. 2016. View Article : Google Scholar : PubMed/NCBI
38	O’Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC and Altieri DC: Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA. 97:13103–13107. 2000. View Article : Google Scholar
39	Perkins ND: Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene. 25:6717–6730. 2006. View Article : Google Scholar : PubMed/NCBI